Needham analyst Michael Matson (NYSE:MATX) reiterated a Buy rating on Medtronic (NYSE:MDT) on Tuesday, setting a price target of $152, which is approximately 18.31% above the present share price of $128.48.
Matson expects Medtronic to post earnings per share (EPS) of $1.01 for the third quarter of 2021.
The current consensus among 15 TipRanks analysts is for a Strong Buy rating of shares in Medtronic, with an average price target of $143.
The analysts price targets range from a high of $152 to a low of $135.
In its latest earnings report, released on 04/30/2021, the company reported a quarterly revenue of $8.19 billion and a net profit of $1.66 billion. The company's market cap is $172.66 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.5% and a 64.94% success rate.
Founded in 1949, Medtronic Plc, a medical technology company, develops, manufactures, distributes, and sells device-based medical therapies and services worldwide. It operates through four segments, including Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The company is headquartered in Dublin, Ireland.